TC
VKTX icon

Truvestments Capital’s Viking Therapeutics VKTX Stock Holding History

Truvestments Capital’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-42
Closed -$1.37K – 1294
2026
Q1 		$1.37K Sell
42
-45
-52% -$1.45K ﹤0.01% 1029
2025
Q4 		$3.06K Hold
87
– – ﹤0.01% 857
2025
Q3 		$2.29K Sell
87
-114
-57% -$3.4K ﹤0.01% 913
2025
Q2 		$5.33K Hold
201
– – ﹤0.01% 727
2025
Q1 		$4.85K Sell
201
-63
-24% -$1.99K ﹤0.01% 752
2024
Q4 		$10.6K Buy
264
+160
+154% +$9.12K ﹤0.01% 591
2024
Q3 		$6.58K Buy
+104
New +$6.1K ﹤0.01% 646
2019
Q3 		– Sell
-1,000
Closed -$8K – 730
2019
Q2 		$8K Buy
+1,000
New +$8.54K 0.01% 565

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Truvestments Capital's VKTX Position: Q2 2026 in Review

Truvestments Capital sold out of Viking Therapeutics (VKTX) in Q2 2026, closing a stake of 42 shares — an estimated $1.37K sold.

Truvestments Capital first reported a position in VKTX in Q2 2019 and held it in 8 quarters. The position peaked at $10.6K in Q4 2024. 432 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

  • Truvestments Capital reported no remaining Viking Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Truvestments Capital sold 42 Viking Therapeutics shares in Q2 2026, an estimated $1.37K.
  • Truvestments Capital first reported a position in Viking Therapeutics in Q2 2019 and held it in 8 quarters.
  • Truvestments Capital's Viking Therapeutics position peaked at $10.6K in Q4 2024.
  • 432 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on Truvestments Capital's 13F filing for Q2 2026, filed 12 Aug 2026.